All In Biotech

Investigational drug · Phase 2

Daplusiran

Also called: Tomligisiran

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Hepatitis B Virus Infection, Hepatitis B.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "Daplusiran"

First trial start

2024

Nov 11, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Daplusiran", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Chronic Hepatitis B Virus Infection
  • Hepatitis B

Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "Daplusiran" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Chronic Hepatitis B Virus Infection

  • ElebsiranVIR-2218, BRII-835Phase 38 trials

    Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection

  • Peg-IFN-αpegylated interferonPhase 26 trials

    Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic

  • HT-101Phase 23 trials

    Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection

  • HT-102Phase 23 trials

    Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection

  • HH-006Phase 21 trial

    Huahui Health · Chronic Hepatitis B Virus Infection

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.